Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

PDS Biotechnology To Rally Around 129%? Here Are 5 Other Price Target Changes For Tuesday

Published 15/11/2022, 12:26
© Reuters.  PDS Biotechnology To Rally Around 129%? Here Are 5 Other Price Target Changes For Tuesday
IXIC
-
TGTB34
-
RCOR
-

Benzinga -

  • Chardan Capital raised PDS Biotechnology Corporation (NASDAQ: PDSB) price target from $15 to $16. . Chardan Capital analyst Geulah Livshits maintained the stock with a Buy rating. PDS Biotechnology shares rose 26.1% to close at $7.06 on Monday.
  • SVB Leerink boosted the price target on Lantheus Holdings, Inc. (NASDAQ: LNTH) from $110 to $120. SVB Leerink analyst Roanna Ruiz maintained an Outperform rating on the stock. Lantheus Holdings shares rose 1.4% to close at $57.25 on Monday.
  • Oppenheimer cut Akoustis Technologies, Inc. (NASDAQ: AKTS) price target from $8 to $7. Oppenheimer analyst Rick Schafer maintained an Outperform rating on the stock. Akoustis Technologies shares fell 2.2% to $3.49 in pre-market trading.
  • Barclays (LON:BARC) raised ImmunoGen, Inc. (NASDAQ: IMGN) price target from $8 to $9. Barclays analyst Peter Lawson maintained an Overweight rating on the stock. ImmunoGen jumped 10.4% to $6.36 in pre-market trading.
  • Piper Sandler raised Shoals Technologies Group, Inc. (NASDAQ: SHLS) price target from $28 to $30. Piper Sandler analyst Kashy Harrison maintained the stock with a Neutral. Shoals Technologies shares gained 17.3% to $26.36 in pre-market trading.
  • Chardan Capital reduced Better Therapeutics, Inc. (NASDAQ: BTTX) price target from $17 to $14. Chardan Capital analyst Keay Nakae maintained a Buy rating on the stock. Better Therapeutics shares rose 1% to $1.50 in pre-market trading.
0700

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.